Optibiotix inks licensing agreement for probiotic strain in Uruguay
Francesca Morgan
Company News - 2 mins
11:00, 12th February 2020

London-listed Optibiotix Health’s (AIM:OPTI) FOLLOW wholly owned subsidiary, ProBiotix, has signed a licensing agreement with Uruguayan dairy producer Granja Pocha to include the group’s probiotic strain, LPLDL®, into a functional yogurt product.

Under a non-exclusive licence, biotechnology company, SACCO S.r.l, will supply ProBiotix's cholesterol and blood pressure-reducing probiotic strain, Lactobacillus plantarum LPLDL®.

SACCO S.r.l, which helped develop the yogurt formulation, will supply the strain to Granja Pocha to include within fermented milk products, such as yogurts, in Uruguay.

Optibiotix said the aim of the licensing agreement is to maximise the financial return for both Granja Pocha and ProBiotix. 

Granja Pocha, who describe themselves as having become one of Uruguay's largest and most respected dairy producers, have sold dairy products under the Colonial brand since 2013.

Shares in OptiBiotix Health were trading flat at 62.5p during Wednesday trading.

The producer was founded in 1980 in the main dairy basin of the Río de la Plata, Juan Lacaze, department of Colonia in Uruguay, the statement detailed.

The licensing agreement represents ProBiotix’s efforts to expand the LPLDL® presence into South America and extend its use into dairy products. 

“The work carried out by Granja Pocha is a significant milestone as it extends the use of LPLDL® into functional foods, in this case dairy, which may be replicated in other territories,” said Steve Prescott, CEO of ProBiotix.

Optibiotix recently hailed its commercial progress in a January trading update for the year ended 30 November 2019 after the group’s geographic reach and brand presence reached 24 new countries during the period.

Within Optibiotix’s portfolio, LPLDL® is, amongst others, expected to contribute to solid revenue growth in 2020 as the company focuses on extending its range of products into new areas.

Follow News & Updates from Optibiotix Health here: FOLLOW

Disclaimer & Declaration of Interest

The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.

Login or register to post comments

Recent Articles